Plasma proteome analysis of patients with type 1 diabetes with diabetic nephropathy

Proteome Science

Volumn 8, Issue , 2010, Pages

  Overgaard, Anne J ^a   Hansen, Henning G ^a   Lajer, Maria ^b   Pedersen, Lykke ^c   Tarnow, Lise ^b   Rossing, Peter ^b   McGuire, James N ^a   Pociot, Flemming ^a  

^a HAGEDORN RESEARCH INSTITUTE   (Denmark)

^b STENO DIABETES CENTER   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN C1; BIOLOGICAL MARKER; CYSTATIN C; HEXAPEPTIDE; PREALBUMIN;

ADULT; ANION EXCHANGE CHROMATOGRAPHY; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIABETIC PATIENT; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; PROTEIN ANALYSIS; PROTEOMICS; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

EID: 77349103013     PISSN: None     EISSN: 14775956     Source Type: Journal    
DOI: 10.1186/1477-5956-8-4     Document Type: Article

References (31)

1. Caramori ML, Fioretto P, Mauer M. Enhancing the Predictive Value of Urinary Albumin for Diabetic Nephropathy. J Am Soc Nephrol 2006, 17:339-352. 10.1681/ASN.2005101075, 16394108.
2. Hovind P, Tarnow L, Rossing K, Rossing P, Eising S, Larsen N, Binder C, Parving H-H. Decreasing Incidence of Severe Diabetic Microangiopathy in Type 1 Diabetes. Diabets Care 2003, 26:1258-1264.
3. Finne P, Reunanen A, Stenman S, Groop P-H, Gronhagen-Riska C. Incidence of End-stage Renal Disease in Patients With Type 1 Diabetes. JAMA 2005, 294:1782-1787. 10.1001/jama.294.14.1782, 16219881.
4. Daneman D. Type 1 diabetes. The Lancet 2006, 367:847-858.
5. Cameron JS. The discovery of diabetic nephropathy: from small print to centre stage. J Nephrol 2006, 75-87.
6. Kilpatrick ES, Rigby AS, Atkin SL. HbA1c variability and the risk of microvascular complications in type 1 diabetes: data from the DCCT. Diabetes Care 2008, dc08-0864.
7. Mogensen CE. Long-Term Antihypertensive Treatment Inhibiting Progression of Diabetic Nephropathy. Brit Med J 1982, 285:685-688.
8. Ahmad J. Renin-angiotensin system blockade in diabetic nephropathy. Diabetes and Metabolic Syndrome: Clinical Research and Reviews 2008, 2:135-158.
9. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, . The Collaborative Study G The Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic Nephropathy. N Engl J Med 1993, 329:1456-1462. 10.1056/NEJM199311113292004, 8413456, The Collaborative Study G.
10. Otu HH, Can H, Spentzos D, Nelson RG, Hanson RL, Looker HC, Knowler WC, Monroy M, Libermann TA, Karumanchi SA, Thadhani R. Prediction of Diabetic Nephropathy Using Urine Proteomic Profiling 10 Years Prior to Development of Nephropathy. Diabetes Care 2007, 30:638-643. 10.2337/dc06-1656, 17327333.
11. Rossing K, Mischak H, Dakna M, Zurbig P, Novak J, Julian BA, Good DM, Coon JJ, Tarnow L, Rossing P, . on behalf of the PN Urinary Proteomics in Diabetes and CKD. J Am Soc Nephrol 2008, 19:1283-1290. 10.1681/ASN.2007091025, 2440301, 18448586, on behalf of the PN.
12. Gu W, Zou LX, Shan PF, Chen YD. Analysis of urinary proteomic patterns for diabetic nephropathy by ProteinChip. Proteom Clin APPL 2008, 2:744-750.
13. Hyun-Jung K, Hyun-Syuk Y, Chan-Wha K. Proteomics in diabetic nephropathy. Proteom Clin APPL 2008, 2:301-311.
14. Kim HJ, Cho EH, Yoo JH, Kim PK, Shin JS, Kim MR, Kim CW. Proteome Analysis of Serum from Type 2 Diabetics with Nephropathy. J Proteome Res 2007, 6:735-743. 10.1021/pr060489g, 17269729.
15. Eun-Hee C, Mi-Ryung K, Hyun-Jung K, Do-Yeon L, Pan-Kyeom K, Kyung MC, Ohk-Hyun R, Chan-Wha K. The discovery of biomarkers for type 2 diabetic nephropathy by serum proteome analysis. Proteom Clin APPL 2007, 1:352-361.
16. McGuire JN, Overgaard J, Pociot F. Mass spectrometry is only one piece of the puzzle in clinical proteomics. Brief Funct Genomic Proteomic 2008, eln005.
17. Boschetti E, Righetti PG. The ProteoMiner in the proteomic arena: A non-depleting tool for discovering low-abundance species. J Proteomics 2008, 71:255-264. 10.1016/j.jprot.2008.05.002, 18603494.
18. Hyvärinen A, Oja E. Independent component analysis: algorithms and applications. Neural Networks 2000, 13:411-430. 10.1016/S0893-6080(00)00026-5, 10946390.
19. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society 1995, 57:289-300.
20. Zhang L, Krzentowski G, Albert A, Lefèbvre PJ. Factors predictive of nephropathy in DCCT Type 1 diabetic patients with good or poor metabolic control. Diabetic Med 2003, 20:580-585. 10.1046/j.1464-5491.2003.00986.x, 12823241.
21. Vilarrasa N, Soler J, Montanya E. Regression of microalbuminuria in type 1 diabetic patients: results of a sequential intervention with improved metabolic control and ACE inhibitors. Acta Diabetologica 2005, 42:87-94. 10.1007/s00592-005-0184-0, 15944842.
22. Hirano T, Sakaue T, Misaki A, Murayama S, Takahashi T, Okada K, Takeuchi H, Yoshino G, Adachi M. Very low-density lipoprotein-apoprotein CI is increased in diabetic nephropathy: Comparison with apoprotein CIII. Kidney Int 2003, 63:2171-2177. 10.1046/j.1523-1755.2003.00019.x, 12753304.
23. Raila J, Henze A, Spranger J, Mohlig M, Pfeiffer AFH, Schweigert FJ. Microalbuminuria is a major determinant of elevated plasma retinol-binding protein 4 in type 2 diabetic patients. Kidney Int 2007, 72:505-511. 10.1038/sj.ki.5002372, 17568782.
24. Jenkins AJ, Lyons TJ, Zheng D, Otvos JD, Lackland DT, McGee D, Garvey WT, Klein RL. Lipoproteins in the DCCT/EDIC cohort: Associations with diabetic nephropathy. Kidney Int 2003, 64:817-828. 10.1046/j.1523-1755.2003.00164.x, 12911531.
25. Mojiminiyi OA, Abdella N. Evaluation of cystatin C and [beta]-2 microglobulin as markers of renal function in patients with type 2 diabetes mellitus. Journal of Diabetes and its Complications 2003, 17:160-168. 10.1016/S1056-8727(02)00177-0, 12738401.
26. Mussap M, Vestra MD, Fioretto P, Saller A, Varagnolo M, Nosadini R, Plebani M. Cystatin C is a more sensitive marker than creatinine for the estimation of GFR in type 2 diabetic patients. Kidney Int 2002, 61:1453-1461. 10.1046/j.1523-1755.2002.00253.x, 11918752.
27. Mantini D, Petrucci F, Del Boccio P, Pieragostino D, Di Nicola M, Lugaresi A, Federici G, Sacchetta P, Di Ilio C, Urbani A. Independent component analysis for the extraction of reliable protein signal profiles from MALDI-TOF mass spectra. Bioinformatics 2008, 24:63-70. 10.1093/bioinformatics/btm533, 18003646.
28. Bonsnes RW, Taussky HH. On the Colorimetric Determination of Creatinine by the Jaffe Reaction. J Biol Chem 1945, 158:581-591.
29. Maggie Merchant SRW Recent advancements in surface-enhanced laser desorption/ionization-time of flight-mass spectrometry. ELECTROPHORESIS 2000, 21:1164-1177. 10.1002/(SICI)1522-2683(20000401)21:6<1164::AID-ELPS1164>3.0.CO;2-0, 10786889, Maggie Merchant SRW.
30. Hutchens TW, Yip TT. New desorption strategies for the mass spectrometric analysis of macromolecules. Rapid Communications in Mass Spectrometry 1993, 7:576-580.
31. Perkins DN, Pappin DJC, Creasy DM, Cottrell JS. Probability-based protein identification by searching sequence databases using mass spectrometry data. ELECTROPHORESIS 1999, 20:3551-3567. 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2, 10612281.